Portal de Periódicos da CAPES

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

2021; Massachusetts Medical Society; Volume: 385; Issue: 13 Linguagem: Inglês

10.1056/nejmoa2103485

1533-4406

Paul Nathan, Jessica C. Hassel, Piotr Rutkowski, Jean‐François Baurain, Marcus O. Butler, Max Schlaak, Ryan J. Sullivan, Sebastian Ochsenreither, Reinhard Dummer, John M. Kirkwood, Anthony M. Joshua, Joseph J. Sacco, Alexander N. Shoushtari, Marlana Orloff, Josep M. Piulats, Mohammed Milhem, April K.S. Salama, Brendan D. Curti, Lev Demidov, Lauris Gastaud, Cornelia Mauch, Melinda Yushak, Richard D. Carvajal, Omid Hamid, Shaad E. Abdullah, Chris Holland, Howard Goodall, Sophie Piperno‐Neumann,

Virus-based gene therapy research

Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100–positive cells.